Bolin Liu, MD


Department of Genetics
Stanley S. Scott Cancer Center
Telephone: 504-210-3328
Fax: 504-210-2970
Email: bliu2@lsuhsc.edu


1987     M.D. in Medicine 
             Beijing Medical University, Beijing, China

1994     M.S. in Molecular Biology
             Institute of Hematology, Chinese Academy of Medical
             Sciences and Peking Union of Medical Colleges, 
             Tianjin, China

2002     Post Doctoral Fellow in Cancer Biology
             The University of Texas MD Anderson Cancer Center
             Houston, TX



Research Interests

My research interests focus on HER2/HER3 receptor tyrosine kinases (RTKs)-initiated cell signaling in cancer development and noncoding RNAs (ncRNAs)-mediated epigenetic regulation of drug resistance and tumor metastasis. By understanding the signal transduction pathways in tumorigenesis and epigenetic mechanisms contributing to the progression of HER2-positive breast cancer and triple-negative breast cancer (TNBC) as well as non-small cell lung cancer (NSCLC), I hope to identify novel molecular targets and develop epigenetic approaches with therapeutic potential for cancer treatment. 

Selected Publications


Hui Lyu, Shuiliang Wang, Jingcao Huang, Bolun Wang, Zhimin He, and Bolin Liu.Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer.Cancer Letters 2018; 420: 97-108 https://doi.org/10.1016/j.canlet.2018.01.065

Bolun Wang, Hui Lyu, Shanshan Pei, Deye Song, Jiangdong Ni, and Bolin Liu. Cladribine in combination with entinostat synergistically elicits anti-proliferative/anti-survival effects on multiple myeloma cells. Cell Cycle 2018; 17:985-996

Hui Lyu, Jingcao Huang, Zhimin He, and Bolin Liu. Targeting of HER3 with functional cooperative miRNAs enhances therapeutic activity in HER2-overexpressing breast cancer cells. Biological Procedures Online 2018; 20:16

Hui Lyu, XiaoHe Yang, Susan M. Edgerton, Ann D. Thor, Xiaoying Wu, Zhimin He, and Bolin Liu. The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells. Oncotarget 2016;7(3): 2921-2935 DOI: 10.18632/oncotarget.6404

Shuiliang Wang, Ling Zhu, Weimin Zuo, Zhiyong Zeng, Lianghu Huang, Fengjin Lin, Rong Lin, Jin Wang, Jun Lu, Qinghua Wang, Lingjing Lin, Huiyue Dong, Weizhen Wu, Kai Zheng, Jinquan Cai, Shunliang Yang, Yujie Ma, Shixin Ye, Wei Liu, Yinghao Yu, Jianming Tan, and Bolin Liu. MicroRNA-mediated epigenetic targeting of Survivin significantly enhances the antitumor activity of paclitaxel against non-small cell lung cancer. Oncotarget 2016;7(25): 37693-37713 DOI: 10.18632/oncotarget.9264

Ying Wu, Hui Lyu, Hongbing Liu, Xuefei Shi, Yong Song, and Bolin Liu. Downregulation of the long noncoding RNA GAS5-AS1 contributes to tumor metastasis in non-small cell lung cancer. Scientific Reports 2016;6, 31093; doi: 10.1038/srep31093

Jingcao Huang, Hui Lyu, Jianxiang Wang, and Bolin Liu. Influence of survivin-targeted therapy on chemosensitivity in the treatment of acute myeloid leukemia. Cancer Letters 2015; 366: 160-172. doi:10.1016/j.canlet.2015.05.033

Hui Lyu, Jingcao Huang, Susan M Edgerton, Ann D Thor, Zhimin He, and Bolin Liu. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells. International Journal of Clinical and Experimental Pathology 2015;8(6):6143-6156

Jian Ma, Hui Lyu, Jingcao Huang, and Bolin Liu. Targeting of erbB3 receptor to overcome resistance in cancer treatment. Molecular Cancer 2014;13:105 doi:10.1186/1476-4598-13-105

Shuiliang Wang, Jingcao Huang, Hui Lyu, Choon-Kee Lee, Jianming Tan, Jianxiang Wang, and Bolin Liu. Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells. Cell Death & Disease 2013;4: e556; doi:10.1038/cddis.2013.79

Shuiliang Wang, Jingcao Huang, Hui Lyu, Bo Cai, Xiaoping Yang, Fang Li, Jianming Tan, Susan M. Edgerton, Ann D Thor, Choon-Kee Lee, and Bolin Liu. Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer. Breast Cancer Research 2013;15:R101. doi:10.1186/bcr3563

Jingcao Huang, Shuiliang Wang, Hui Lyu, Bo Cai, XiaoHe Yang, Jianxiang Wang, and Bolin Liu. The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells. Molecular Cancer 2013;12:134  doi:10.1186/1476-4598-12-134

Xiaoping Huang, Shuiliang Wang, Choon-Kee Lee, XiaoHe Yang, and Bolin Liu. HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance. Cancer Letters 2011;307(1):72-9. doi:10.1016/j.canlet.2011.03.019

Shuiliang Wang, Xiaoping Huang, Choon-Kee Lee, and Bolin Liu. Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin. Oncogene 2010;29: 4225–4236

Xiaoping Huang, Lizhi Gao, Shuiliang Wang, James L. McManaman, Ann D. Thor, Xiaohe Yang, Francisco J. Esteva, and Bolin Liu. Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-I receptor in breast cancer cells resistant to Herceptin. Cancer Research 2010;70(3):1204-1214

Xiaoping Huang, Lizhi Gao, Shuiliang Wang, Choon-Kee Lee, Peter Ordentlich, and Bolin Liu. HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via downregulation of erbB3 expression. Cancer Research 2009;69(21):8403-8411

Additional Info